Stocks
Axsome Therapeutics, Inc.AXSM
NASDAQHealthcareBiotechnology$156.08+1.27%
Focused on developing novel therapies for central nervous system disorders, this biopharmaceutical company has gained investor attention for its late-stage pipeline targeting depression and migraine. The firm's recent FDA approval for a major depressive disorder treatment has positioned it as a potential disruptor in the neuroscience space.
Market Cap: $8.0B52W Range: $86.99 – $191.50
Congressional Interest in Axsome Therapeutics, Inc. (AXSM)
2 members of Congress have disclosed 2 trades in Axsome Therapeutics, Inc. (AXSM), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
1
Sells
1
Who in Congress Is Trading AXSM?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-06-16 | Christopher L. Jacobs | buy | $15K – $50K |
| 2020-12-10 | Kurt Schrader | sell | $1K – $15K |